Eritoran
id:
eritoran-238-2742861
title:
Eritoran
text:
Eritoran is a synthetic lipid that inhibits the receptor TLR4. It was developed as a potential treatment for severe sepsis, an excessive inflammatory response to an infection. It failed a five year Phase III clinical trial, the results of which were published in 2013, and as of 2014 was no longer being developed. It was being developed by the Japanese pharmaceutical company Eisai Co. and was administered intravenously as the sodium salt eritoran tetrasodium. TLR4 is part of the innate immune sys
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Eritoran
date created:
date modified:
2023-11-04T17:55:29Z
main entity:
{"identifier":"Q5389586","url":"https://www.wikidata.org/entity/Q5389586"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/0/02/Eritoran_free_acid_skeletal.svg","width":623,"height":262}
fields total:
13
integrity:
15